---
title: "688185.SH (688185.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688185.SH/news.md"
symbol: "688185.SH"
name: "688185.SH"
parent: "https://longbridge.com/en/quote/688185.SH.md"
datetime: "2026-05-21T10:16:46.022Z"
locales:
  - [en](https://longbridge.com/en/quote/688185.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688185.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688185.SH/news.md)
---

# 688185.SH (688185.SH) — Related News

### [CanSinoBIO: The NDA for Td5cp for adolescents and adults has been included in the priority review by the National Medical Products Administration's Drug Evaluation Center](https://longbridge.com/en/news/285908930.md)
*2026-05-11T08:51:05.000Z*
> CanSinoBIO announced that its new drug application (NDA) for the Td5cp vaccine for adolescents and adults has been inclu

### [UBS: Lowers CanSinoBIO target price to HKD 52.4, first quarter performance meets expectations](https://longbridge.com/en/news/284722885.md)
*2026-04-30T08:14:06.000Z*
> UBS released a research report stating that CANSINOBIO's performance in the first quarter of this year met expectations.

### [](https://longbridge.com/en/news/284474559.md)
*2026-04-29T01:41:03.000Z*
> CANSINOBIO's Hong Kong stock price fell by 5.1%, closing at HKD 30.40 per share

### [The three major A-share indices of Shanghai and Shenzhen opened lower by 0.4%-0.5%, chip stocks showed weakness, and China Merchants Bank opened lower by 1.7% after earnings](https://longbridge.com/en/news/284475036.md)
*2026-04-29T01:33:33.000Z*
> The three major A-share indices opened lower by 0.4%-0.5%. The Shanghai Composite Index reported 4,061 points, down 16 p

### [CanSinoBIO Q1 revenue increased by nearly 40%, as expenses led to an expanded loss, with reliance on core products needing resolution](https://longbridge.com/en/news/284395835.md)
*2026-04-28T13:27:19.000Z*
> CanSinoBIO's Q1 2026 report shows revenue of 190 million yuan, a year-on-year increase of 38.73%, but the net profit att

### [CanSinoBIO's first-quarter performance shows steady growth, and its full lifecycle layout opens up long-term value space](https://longbridge.com/en/news/284397176.md)
*2026-04-28T13:14:51.000Z*
> CanSinoBIO / Released the Q1 2026 financial report, with operating revenue reaching 190 million yuan, a year-on-year inc

### [CanSinoBIO Delivers Q1 Revenue Growth Amid Accelerating International Expansion](https://longbridge.com/en/news/284372615.md)
*2026-04-28T11:20:44.000Z*
> CanSino Biologics Inc. reported a 38.73% year-over-year revenue increase in Q1 2026, totaling RMB 190 million. The growt